Introduction
Hypertrophic cardiomyopathy (HCM) is the most prevalent heritable cardiovascular disease. It is characterized by asymmetric hypertrophy of the left ventricle out of proportion to what can be explained by other cardiac or systemic diseases. The prevalence of HCM is 1 in 500 people (0.2% of population), 1 and it is a common cause of sudden cardiac death in young people. 2, 3 Dynamic left ventricular outflow tract (LVOT) obstruction is present either at rest or with exercise in 70% of HCM patients. 4 Understanding of HCM has increased remarkably in the past several decades due to improved imaging quality and evolving genetic links identified by mutations in the cardiac sarcomeric proteins. 5 However, its clinical landscape continues to be diverse and is rapidly changing. Aortic dilation is a major cause of morbidity and mortality in the U.S. 6 The prevalence of aortic dilation depends on the criteria used for defining aortic dilation, ranging from 2.2% after adjusting for body surface area (BSA) to 7.6% using absolute cut-offs of >40 mm for men and >36 mm for women in the general population. 7, 8 Aortic dilation is associated with Marfan syndrome, bicuspid aortic valve, LoeysDietz syndrome, Ehlers-Danlos syndrome, and other cardiac or systemic diseases. 9 The pathophysiologic basis of aortic dilation with other diseases has been proposed to be either genetic or hemodynamic. In our HCM centre, we made an observation of a hitherto 
Methods
A multidisciplinary HCM centre has been operating at our regional tertiary referral centre since January 2011. All patients referred to this HCM centre for further evaluation and management from Jan. 1, 2011 to March 31, 2014 were included in this study. Comprehensive geno-phenotypic and clinical evaluations, as well as comprehensive imaging examinations, were performed as clinically indicated. Genetic testing was offered to all patients after genetic counseling was completed and informed consent obtained. Approval was given by the Institutional Review Board. Clinical and imaging data of all patients were collected and analyzed retrospectively from our HCM clinic database; this included baseline demographic, personal and family medical history, and imaging data. Information regarding the patients' clinical course, management, and follow-up-including medications, septal reduction interventions, and genetic testing-was analyzed. Genetic testing for HCM, which involved use of commercially available panels and included the sarcomeric contractile proteins as well as other genes known to cause HCM phenocopy, 10 was offered to all patients. Patients with a dilated aorta were offered thoracic aortic aneurysm and dissection (TAAD) gene testingcomprising alpha-actin 2, cystathionine-b-synthase, collagen alpha chain (COL3A1, COL5A1, and COL5A2), fibrillin (FBN1, FBN2), filamin A, mediator complex subunit 12, myosin heavy chain (MYH), SKI, solute carrier family 2, SMAD3, transforming growth factor beta (TGF-b2), and transforming growth factor beta receptors (TGF-b R1, TGF-b R2)-as well.
All patients underwent complete two-dimensional and Doppler echocardiographic examinations as recommended by American Society of Echocardiography and European Association of Cardiovascular Imaging published guidelines. [11] [12] [13] [14] The leading edge-to-leading edge technique was used to measure the sinuses of Valsalva and ascending aorta at enddiastole as proposed by recent American Society of Echocardiography and European Association of Cardiovascular Imaging published guidelines. 15 In patients who underwent computed tomography (CT) or cardiac magnetic resonance (CMR) imaging, an inner edge-to-inner edge approach was used for measuring sinuses of Valsalva (average of sinus-tocommissure measurement of 3 sinuses in end-diastole in sinus-of-Valsalva plane) and the ascending aortic dimensions (using a double oblique image for orientation). 15 Aortic dilation was defined as proposed by recent American Society of Echocardiography and European Association of Cardiovascular Imaging published guidelines 15 after considering age, gender, and BSA. Continuous variables are summarized as mean ± standard deviation, and categorical data are summarized as frequencies and percentages. Pearson correlation was calculated to summarize the degree of correlation between echocardiogram measures of sinuses of Valsalva and ascending aorta and those obtained from chest CT and CMR imaging modalities. Comparisons of continuous variables between patients with or without dilated aorta were made using Wilcoxon rank-sum tests. Comparisons of categorical variables were done using Chi-square tests and Fisher's exact tests when appropriate. All analyses were performed using SAS statistical software (version 9.2; SAS Institute, Inc., Cary, NC).
Results
From January 2011 through March 2014, 262 patients and family members were evaluated at our HCM centre. After comprehensive geno-phenotypic evaluation, 201 patients who were phenotype positive for HCM were included in our study. We excluded phenotypeand genotype-negative family members of HCM patients and patients who were diagnosed with HCM phenocopies.
Using the definition of sinuses of Valsalva or ascending aorta diameter >40 mm for a male or >36 mm for a female, 31 patients with HCM (15.4%) met the definition of dilated aorta; however, applying the recent American Society of Echocardiography and European Association of Cardiovascular Imaging published guidelines 15 for defining dilated aorta, 18 patients with HCM (9.0%) were diagnosed with aortic dilation, and this number was used in the analysis. Baseline and echocardiographic characteristics of HCM patients with aortic dilation are summarized in Table 1 and compared with HCM patients without aortic dilation. Mean age of the HCM patients with aortic dilation at the time of diagnosis was 56.3 ± 9.3 years; 14 patients (77.8%) were male, 6 patients (33.3%) had hypertension, and 8 patients (44.4%) had obstructive sleep apnea. Of the 18 patients with HCM and a dilated aorta, hypertrophy involved the base in 9 patients (50.0%), apex in 1 (5.6%), and midventricle in 5 (27.7%); concentric hypertrophy was noted in 3 patients (16.7%). Maximum LV wall thickness was 2.1 ± 0.5 cm. LVOT obstruction, which was defined as a peak LVOT gradient > _30 at rest or with provocation, was noted in 13 patients (72.2%) with a peak gradient of 73.7 ± 46.1 mm Hg. Mean global longitudinal strain was reduced (-14.4% ± 4.7). Mitral regurgitation was noted in 17 patients (94.4%) and aortic regurgitation (trace to mild) in 9 patients (50.0%). All patients had tri-leaflet aortic valves. Aortic valve stenosis was not noted in any of the patients. The mean diameters of the sinuses of Valsalva and ascending aorta were 4.2 ± 0.2 cm and 4.0 ± 0.4 cm, respectively, for males and 3.8 ± 0.4 cm and 3.8 ± 0.2 cm for females.
Of the 18 members of the HCM with a dilated aorta cohort, in addition to echocardiogram, 6 patients (33.3%) had CMR, 11 patients (61.1%) had a chest CT, and 4 patients (22.2%) underwent CMR and CT. On CMR, the mean sinuses of Valsalva diameter was 4.1 ± 0.4 cm and mean ascending aorta diameter was 3.8 ± 0.2 cm. On CT, the mean sinuses of Valsalva diameter was 4.1 ± 0.3 cm and mean ascending aorta diameter was 3. (Figure 1) .
Of the 18 patients who were diagnosed with aortic dilation, 7 patients (38.9%) were diagnosed based on a dilated sinus of Valsalva with a mean diameter of 4.2 ± 0.3 cm and 11 patients (61.1%) were diagnosed based on a dilated ascending aorta with a mean diameter of 4.1 ± 0.3 cm. Five out of 7 (71%) patients with a dilated sinus of Valsalva and 8 out of 11 (73%) patients with a dilated ascending aorta had LVOT obstruction, which was not statistically significant (P = 0.93).
Two patients (11.1%) underwent alcohol septal ablation, 1 patient (5.6%) underwent myectomy, 1 (5.6%) patient underwent myectomy and ascending aorta grafting, and 5 (27.8%) patients required implantable cardioverter defibrillator placement. No patient required aortic or mitral valve surgery. HCM patients with a dilated aorta were more likely to be male (77.8% vs. 51.9%, P = 0.04), had a larger BSA (2.1 ± 0.2 vs. 1.9 ± 0.3, P = 0.003), were less likely to be hypertensive (33.3% vs. 60.7% P = 0.03), and had higher prevalence of aortic valve regurgitation (trace to mild) (50.0% vs. 22.4%, P = 0.003). The rest of the clinical and echocardiographic characteristics were similar between these two groups ( 
Discussion
At our institution, using the definition of sinuses of Valsalva or ascending aorta diameter >40 mm for a male or >36 mm for a female, 31 patients with HCM (15.4%) met the definition of dilated aorta; however, after adjusting for age, sex, and BSA by applying the recent American Society of Echocardiography and European Association of Cardiovascular Imaging published guidelines 15 for defining dilated aorta, 18 patients with HCM (9.0%) were diagnosed with aortic dilation. The prevalence of aortic dilation that has been reported in the literature depends on the criteria used for defining aortic dilation, ranging from 2.2% after adjusting for BSA to 7.6% using absolute cutoffs of >40 mm for males and >36 mm for females in the general population. 7, 8 Our observation raises the possibility of an association between two diverse entities and leads to questions regarding their pathophysiological and/or genetic association. Thoracic aortic dilation has been well described in association with Marfan syndrome, bicuspid aortic valve, patent ductus arteriosus, mitral valve prolapse, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, and Beals-Hecht syndrome. 9 However, to our knowledge, an association of aortic dilation with HCM has not been described in the literature. This unique subset of patients with concomitant HCM and aortic dilation could be at higher risk for adverse events, including the risk of aortic aneurysm. Thus, the association of HCM and aortic dilation needs to be studied in large populations in order to gain insights into the clinical outcomes of the patients in whom these entities coexist. Additionally, it is important to understand the pathophysiologic basis of this association in order to determine the appropriate surveillance and monitoring. Although further investigation and research is needed to better understand the pathophysiologic basis for the coexistence of HCM and aortic dilation, we hypothesize the following potential explanations. It is well known that altered flow dynamics through a morphologically abnormal aortic valve change the spatial velocity gradients, and thus create a shear stress stimulus on the aortic walls that alters gene expression and promotes endothelial remodeling. 16 This has been well demonstrated in patients with bicuspid aortic valve. Similar altered flow dynamics in patients with obstructive HCM, or alterations in the spatial velocity gradients in the hypertrophied pathologic left ventricle in patients with obstructive and non-obstructive HCM, might contribute to aortic dilation in these patients. These hemodynamic factors might be more pronounced in patients with intrinsic weakness of the aortic wall, especially in those with a genetic predisposition or other comorbidities contributing to the aortic disease. Given a higher prevalence of LVOT obstruction (72.2% vs. 59.0%) in patients with aortic dilation in our cohort, even though not statistically significant, it appears plausible that hemodynamic alterations might be an etiopathogenetic factor for aortic dilation. A study by Boonyasirinant and colleagues showed that aortic stiffness is increased in patients with HCM as compared with a control group. 17 This association was hypothesized to be due to intrinsic aortic fibrosis in HCM, neuro-hormonal disturbance, endothelial dysfunction, or abnormal left ventricular baroreceptor response. 17 The mechanism of most aortopathies has been ascribed to dysregulation of transforming growth factor-beta (TGF-b), which causes weakening and disordering of elastic fiber formation in the aortic wall, leading to aortic dilation; expression of TGF-b gene has been shown to be enhanced in patients with HCM. 10, 18 IGF-I and TGF-b1 signals may be further amplified by increased receptor numbers on cardiomyocytes and fibroblasts. 19, 20 Thus, these genetic and molecular alterations, which can activate similar pathways, might explain to some extent the higher prevalence of aortic dilation in HCM patients, although this needs to be proved further. This hypothesis was recently put to the test by Vizzardi et al. and showed impaired distensibility and stiffness of the aorta in HCM patients compared to the control group.
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In our study, 2 out of 5 patients (40%) with HCM and aortic dilation who were tested for TAAD gene tested positive for mutation; however, the true genetic links between HCM and aortic dilation remain unknown because of the small sample group.
Therefore, it is important to assess the exact prevalence of this association via a collaborative effort across institutions. Careful and detailed evaluation of HCM registry patients might help us understand the genetic, molecular, and hemodynamic interplay that might alter the phenotypic expression and clinical course of these patients. This is especially important since the synergistic effects of these two entities in one patient might have the potential for significantly adverse clinical outcomes.
Our study has some limitations; our HCM centre is a large, community-based tertiary referral centre that serves more than 30% of Wisconsin and northern Illinois residents. One limitation of our study may stem from this "regional bias," wherein the HCM proband's family members often live in the same area, with a clustering of cases. Additionally, our cohort is small and concentrated around a specific patient population, thus it may not represent a realistic incidence of the association of HCM and aortic dilation. Another limitation is that not all the patients had undergone all imaging modalities and a small number of patients had CMR and/or CT; however, all the patients had echocardiogram, which was used for the diagnosis of aortic dilation. Also, TAAD genotyping was performed in a limited number of patients. Large multicentre studies are therefore needed to identify the true incidence of this association in HCM patients and to help understand their pathophysiologic association.
